The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study
Open accessAbstract
OBJECTIVE: To examine the effect of β blockers in the management of chronic obstructive pulmonary disease (COPD), assessing their effect on mortality, hospital admissions, and exacerbations of COPD when added to established treatment for COPD. DESIGN: Retrospective cohort study using a disease specific database of COPD patients (TARDIS) linked to the Scottish morbidity records of acute hospital admissions, the Tayside community pharmacy prescription records, and the General Register Office for Scotland death registry. SETTING: Tayside, Scotland (2001-2010) Population 5977 patients aged >50 years with a diagnosis of COPD. MAIN OUTCOME MEASURES: Hazard ratios for all cause mortality, emergency oral corticosteroid use, and respiratory related hospital admissions calculated through Cox proportional hazard regression after correction for influential covariates. RESULTS: Mean follow-up was 4.35 years, mean age at diagnosis was 69.1 years, and 88% of β blockers used were cardioselective. There was a 22% overall reduction in all cause mortality with β blocker use. Furthermore, there were additive benefits of β blockers on all cause mortality at all treatment steps for COPD. Compared with controls (given only inhaled therapy with either short acting β agonists or short acting antimuscarinics), the adjusted hazard ratio for all cause mortality was 0.28 (95% CI 0.21 to 0.39) for treatment with inhaled corticosteroid, long acting β agonist, and long acting antimuscarinic plus β blocker versus 0.43 (0.38 to 0.48) without β blocker. There were similar trends showing additive benefits of β blockers in reducing oral corticosteroid use and hospital admissions due to respiratory disease. β blockers had no deleterious impact on lung function at all treatment steps when given in conjunction with either a long acting β agonist or antimuscarinic agent CONCLUSIONS: β blockers may reduce mortality and COPD exacerbations when added to established inhaled stepwise therapy for COPD, independently of overt cardiovascular disease and cardiac drugs, and without adverse effects on pulmonary function. NCT Number: NCT01221480
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,830
The natural history of chronic airflow obstruction.
Fletcher, C., & Peto, R. (1977) · BMJ · doi:10.1136/bmj.1.6077.1645 · Cited by 2,370
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
Characterisation of COPD heterogeneity in the ECLIPSE cohort
the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators, Agusti, A., Calverley, P. M., Celli, B., Coxson, H. O., Edwards, L. D., Lomas, D. A., MacNee, W., Miller, B. E., Rennard, S., et al. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-122 · Cited by 1,157
Sin, D. D., & Man, S. F. P. (2003) · Circulation · doi:10.1161/01.cir.0000056767.69054.b3 · Cited by 1,082
Gottlieb, S. S., McCarter, R. J., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 982
Crim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00193908 · Cited by 432
Mancini, G. B. J., Etminan, M., Zhang, B., Levesque, L. E., FitzGerald, J. M., & Brophy, J. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.039 · Cited by 402
Cardioselective beta-blockers for chronic obstructive pulmonary disease
Salpeter, S. R., Ormiston, T. M., & Salpeter, E. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003566.pub2 · Cited by 381
Cited by
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Cardiovascular Comorbidity in COPD
Müllerova, H., Agusti, A., Erqou, S., & Mapel, D. W. (2013) · Chest · doi:10.1378/chest.12-2847 · Cited by 358
COPD and its comorbidities: Impact, measurement and mechanisms
Negewo, N. A., Gibson, P. G., & McDonald, V. M. (2015) · Respirology · doi:10.1111/resp.12642 · Cited by 311
Mining Electronic Health Records (EHRs): A Survey
Yadav, P., Steinbach, M., Kumar, V., & Simon, G. (2018) · ACM Computing Surveys · doi:10.1145/3127881 · Cited by 299
Metadata
- Authors
- Short, P. M., Lipworth, S. I. W., Elder, D. H. J., Schembri, S., & Lipworth, B. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-05-10
- Volume
- 342
- Issue
- may10 2
- Pages
- d2549-d2549
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2074016661
- Cited by
- 270
- References
- 24
- FWCI
- 27.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. https://app.cochat.ai/papers/10.1136/bmj.d2549
- The paper
- Short, P. M., Lipworth, S. I. W., Elder, D. H. J., Schembri, S., & Lipworth, B. J. (2011). Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. https://doi.org/10.1136/bmj.d2549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.